Feb 24, 2026 07:00AM
Feb 23, 2026 07:00AM
Feb 20, 2026 07:53AM
Feb 19, 2026 02:01PM
Feb 17, 2026 07:02AM
Feb 17, 2026 07:00AM
Feb 13, 2026 05:00PM Ocular Therapeutix to announce SOL-1 phase 3 trial results for wet AMD
Feb 13, 2026 05:00PM
Feb 6, 2026 04:01PM
Feb 5, 2026 08:55AM
Feb 5, 2026 07:00AM
Jan 23, 2026 04:01PM
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Dec 9, 2025 04:00AM
Dec 8, 2025 07:02AM
Dec 8, 2025 07:00AM
Dec 8, 2025 06:46AM
Dec 8, 2025 05:08AM
Dec 8, 2025 04:34AM
Dec 5, 2025 07:00AM Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 12, 2025 07:00AM
Nov 7, 2025 07:00AM
Nov 4, 2025 07:05AM
Nov 4, 2025 07:02AM
Nov 4, 2025 07:00AM Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
Oct 28, 2025 07:00AM
Oct 8, 2025 06:45AM
Oct 7, 2025 07:00AM
Sep 30, 2025 07:08AM
Sep 30, 2025 07:08AM
Sep 30, 2025 06:21AM
Sep 30, 2025 06:21AM Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary End
Sep 8, 2025 07:00AM
Aug 27, 2025 07:00AM
Aug 12, 2025 07:01AM
Aug 12, 2025 07:00AM
Aug 5, 2025 11:11AM
Aug 5, 2025 07:00AM
Jul 29, 2025 07:00AM Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Jul 22, 2025 07:00AM
Jun 26, 2025 01:54PM
Jun 16, 2025 07:00AM
May 30, 2025 06:43AM
May 28, 2025 07:00AM
May 14, 2025 07:00AM
May 5, 2025 07:00AM Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
Apr 29, 2025 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All